A Lancet Psychiatry study of over 70,000 records found 24% lower hospitalisation risk. Outside experts say the link is promising but nuanced.
Recap by typeshit. Full story at pharmaphorum.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The law firm explains what Lilly's retatrutide suits mean for pharmacies, telehealth companies and online sellers, as the drug maker goes after unapproved versions.
Medscape reports that people with hidradenitis suppurativa begin GLP-1 drugs sooner in their disease course than people with psoriasis do.
Loading…